Samuel Blackman: Proud to join the board of the Pediatric Brain Tumor Foundation
Samuel Blackman, Founder and Former Head of Research and Development at Day One Biopharmaceuticals, reshared a post by Pediatric Brain Tumor Foundation on LinkedIn:
“I’m very proud to be able to join the board of the Pediatric Brain Tumor Foundation, an organization that I’ve had the pleasure of working closely with for many years.
Now, more than ever, the pediatric oncology and neuro-oncology ecosystem needs to work together, creatively, to find new solutions to funding research and therapeutic development for childhood brain tumors. I’m thrilled to be able to bring a clinical, scientific, and biopharma perspective to the board.
At a time of so much uncertainty, I take great comfort in having found, and been able to join, a diverse, talented, and highly-motivated group of individuals from all walks of life, working together to identify and drive solutions that will positively impact the lives of children living with brain tumors, and their families.”
Quoting Pediatric Brain Tumor Foundation‘s post:
“We are thrilled to announce the addition of Dr. Samuel C. Blackman to the Pediatric Brain Tumor Foundation’s Board of Directors!
Dr. Blackman, co-founder and former Head of Research & Development of Day One Biopharmaceuticals and a physician-scientist in pediatric neuro-oncology, brings a wealth of experience and skill to our team.
His dedication towards developing new treatments for pediatric cancer is unparalleled. At Day One Biopharmaceuticals, he led the acquisition and development of OJEMDA, a breakthrough drug that marks significant progress in the treatment of pediatric low-grade gliomas. His leadership and vision resulted in the drug receiving FDA approval in April 2024, making it the first and only approved treatment for the most common type of brain tumor in children.
Dr. Blackman’s rich understanding of pediatric oncology and drug development are invaluable assets to our cause. His joining our board strengthens our commitment to funding research, raising awareness, and making an impact for pediatric brain tumor patients and their families. We look forward to the advancements we will make together.
Learn more about Dr. Blackman by reading our press release.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023